Search Results - "Pigaditou, A."

PROGNOSTIC FACTORS (PFs) IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL) TREATED WITH RITUXIMAB‐CHOP (RCHOP) ± RADIOTHERAPY (RT) by Vassilakopoulos, T.P., Papageorgiou, S.G., Michail, M., Angelopoulou, M.K., Kourti, G., Kalpadakis, C., Kotsopoulou, M., Leonidopoulou, T., Konstantinidou, P., Kotsianidis, I., Boutsis, D., Michali, E., Sachanas, S., Terpos, E., Karianakis, G., Poziopoulos, C., Vadikolia, C., Pigaditou, A., Vrakidou, E., Anargyrou, K., Symeonidis, A., Stefanoudaki, E., Hadjiharissi, E., Papaioannou, M., Gainaru, G., Tsirogianni, M., Katodritou, E., Karmiris, T., Variami, E., Pappa, V., Dimopoulos, M., Roussou, P., Panayitidis, P., Konstantopoulos, K., Pangalis, G.A.

Get full text

Fludarabine in low-grade lymphoma by Pigaditou, A, Rohatiner, A Z, Whelan, J S, Johnson, P W, Ganjoo, R K, Rossi, A, Norton, A J, Amess, J, Lim, J, Lister, T A

“…During the last 4 years, 88 patients with low-grade non-Hodgkin's lymphoma have received fludarabine, 25 mg/m2 daily for 5 days, repeated every 3 to 4 weeks…”
Get more information

Myelo-ablative therapy with peripheral blood progenitor cell (PBPC) support in patients with haematological malignancy by Pigaditou, A, Marini, G, Johnson, P W, Mahmoud, M, Okukenu, E, Adams, K, Salam, A, Amess, J A, Norton, A J, Murphy, M F

“…Myelo-ablative therapy with peripheral blood progenitor cell (PBPC) support is increasingly being used in patients with haematological malignancy considered to…”
Get more information